Which has better earnings & valuation, KYTX or TLSA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kyverna Therapeutics N/A N/A -$161.31M -$3.28 N/A Tiziana Life Sciences N/A N/A -$18.43M N/A N/A

Is KYTX or TLSA more profitable?

Tiziana Life Sciences' return on equity of 0.00% beat Kyverna Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Kyverna Therapeutics N/A -81.88% -64.87% Tiziana Life Sciences N/A N/A N/A

Does the media refer more to KYTX or TLSA?

In the previous week, Tiziana Life Sciences had 5 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 8 mentions for Tiziana Life Sciences and 3 mentions for Kyverna Therapeutics. Tiziana Life Sciences' average media sentiment score of 1.93 beat Kyverna Therapeutics' score of 0.56 indicating that Tiziana Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyverna Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tiziana Life Sciences 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts prefer PRTA or TLSA?

Prothena presently has a consensus price target of $23.75, suggesting a potential upside of 169.58%. Given Prothena's stronger consensus rating and higher probable upside, equities analysts plainly believe Prothena is more favorable than Tiziana Life Sciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prothena 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.75 Tiziana Life Sciences 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has better earnings & valuation, PRTA or TLSA?

Tiziana Life Sciences has lower revenue, but higher earnings than Prothena. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prothena $54.53M 8.46 -$244.09M -$0.84 N/A Tiziana Life Sciences N/A N/A -$18.43M N/A N/A

Does the media prefer PRTA or TLSA?

In the previous week, Tiziana Life Sciences had 1 more articles in the media than Prothena. MarketBeat recorded 8 mentions for Tiziana Life Sciences and 7 mentions for Prothena. Tiziana Life Sciences' average media sentiment score of 1.93 beat Prothena's score of 0.35 indicating that Tiziana Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prothena 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Tiziana Life Sciences 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts prefer TLSA or BNTC?

Benitec Biopharma has a consensus price target of $24.80, suggesting a potential upside of 84.04%. Given Benitec Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Benitec Biopharma is more favorable than Tiziana Life Sciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tiziana Life Sciences 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Benitec Biopharma 1 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.60

Which has stronger valuation & earnings, TLSA or BNTC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tiziana Life Sciences N/A N/A -$18.43M N/A N/A Benitec Biopharma N/A N/A -$37.92M -$1.14 N/A

Is TLSA or BNTC more profitable?

Tiziana Life Sciences' return on equity of 0.00% beat Benitec Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Tiziana Life Sciences N/A N/A N/A Benitec Biopharma N/A -34.82% -34.11%

Do analysts prefer TLSA or CBIO?

Crescent Biopharma has a consensus target price of $29.40, indicating a potential upside of 74.35%. Given Crescent Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Crescent Biopharma is more favorable than Tiziana Life Sciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tiziana Life Sciences 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Crescent Biopharma 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60

Which has higher earnings & valuation, TLSA or CBIO?

Tiziana Life Sciences has higher earnings, but lower revenue than Crescent Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tiziana Life Sciences N/A N/A -$18.43M N/A N/A Crescent Biopharma $10.84M 57.78 -$153.94M -$6.72 N/A

Is TLSA or CBIO more profitable?

Tiziana Life Sciences' return on equity of 0.00% beat Crescent Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Tiziana Life Sciences N/A N/A N/A Crescent Biopharma N/A -101.50% -86.86%

Does the media refer more to TLSA or CBIO?

In the previous week, Crescent Biopharma had 2 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 10 mentions for Crescent Biopharma and 8 mentions for Tiziana Life Sciences. Tiziana Life Sciences' average media sentiment score of 1.93 beat Crescent Biopharma's score of 0.13 indicating that Tiziana Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tiziana Life Sciences 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Crescent Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend CABA or TLSA?

Cabaletta Bio currently has a consensus target price of $15.50, indicating a potential upside of 460.58%. Given Cabaletta Bio's stronger consensus rating and higher probable upside, analysts plainly believe Cabaletta Bio is more favorable than Tiziana Life Sciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cabaletta Bio 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57 Tiziana Life Sciences 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has better valuation & earnings, CABA or TLSA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cabaletta Bio N/A N/A -$167.86M -$1.96 N/A Tiziana Life Sciences N/A N/A -$18.43M N/A N/A

Is CABA or TLSA more profitable?

Tiziana Life Sciences' return on equity of 0.00% beat Cabaletta Bio's return on equity. Company Net Margins Return on Equity Return on Assets Cabaletta Bio N/A -131.58% -96.46% Tiziana Life Sciences N/A N/A N/A

Does the media refer more to CABA or TLSA?

In the previous week, Tiziana Life Sciences had 7 more articles in the media than Cabaletta Bio. MarketBeat recorded 8 mentions for Tiziana Life Sciences and 1 mentions for Cabaletta Bio. Tiziana Life Sciences' average media sentiment score of 1.93 beat Cabaletta Bio's score of 1.67 indicating that Tiziana Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cabaletta Bio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Tiziana Life Sciences 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Tiziana Life Sciences (TLSA) Competitors

$0.99 -0.01 (-0.60%)

As of 03:40 PM Eastern

Compare

TLSA vs. KYTX, PRTA, BNTC, CBIO, and CABA

Should you buy Tiziana Life Sciences stock or one of its competitors? MarketBeat compares Tiziana Life Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tiziana Life Sciences include Kyverna Therapeutics (KYTX), Prothena (PRTA), Benitec Biopharma (BNTC), Crescent Biopharma (CBIO), and Cabaletta Bio (CABA). These companies are all part of the "biotechnology" industry.

How does Tiziana Life Sciences compare to Kyverna Therapeutics?

Kyverna Therapeutics (NASDAQ:KYTX) and Tiziana Life Sciences (NASDAQ:TLSA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, media sentiment, valuation and dividends.

18.1% of Kyverna Therapeutics shares are owned by institutional investors. 17.6% of Kyverna Therapeutics shares are owned by insiders. Comparatively, 39.8% of Tiziana Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$3.28	N/A
Tiziana Life Sciences	N/A	N/A	-$18.43M	N/A	N/A

Kyverna Therapeutics has a beta of 1.93, indicating that its stock price is 93% more volatile than the broader market. Comparatively, Tiziana Life Sciences has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market.

Tiziana Life Sciences' return on equity of 0.00% beat Kyverna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyverna Therapeutics	N/A	-81.88%	-64.87%
Tiziana Life Sciences	N/A	N/A	N/A

In the previous week, Tiziana Life Sciences had 5 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 8 mentions for Tiziana Life Sciences and 3 mentions for Kyverna Therapeutics. Tiziana Life Sciences' average media sentiment score of 1.93 beat Kyverna Therapeutics' score of 0.56 indicating that Tiziana Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyverna Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tiziana Life Sciences	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Kyverna Therapeutics presently has a consensus target price of $30.00, indicating a potential upside of 276.18%. Given Kyverna Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Kyverna Therapeutics is more favorable than Tiziana Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Tiziana Life Sciences	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Tiziana Life Sciences beats Kyverna Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Tiziana Life Sciences compare to Prothena?

Prothena (NASDAQ:PRTA) and Tiziana Life Sciences (NASDAQ:TLSA) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, media sentiment, analyst recommendations and risk.

Prothena has a beta of -0.3, meaning that its stock price is 130% less volatile than the broader market. Comparatively, Tiziana Life Sciences has a beta of 0.49, meaning that its stock price is 51% less volatile than the broader market.

Tiziana Life Sciences has lower revenue, but higher earnings than Prothena.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prothena	$54.53M	8.46	-$244.09M	-$0.84	N/A
Tiziana Life Sciences	N/A	N/A	-$18.43M	N/A	N/A

97.1% of Prothena shares are held by institutional investors. 10.4% of Prothena shares are held by insiders. Comparatively, 39.8% of Tiziana Life Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Tiziana Life Sciences has a net margin of 0.00% compared to Prothena's net margin of -80.68%. Tiziana Life Sciences' return on equity of 0.00% beat Prothena's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prothena	-80.68%	-16.45%	-14.51%
Tiziana Life Sciences	N/A	N/A	N/A

In the previous week, Tiziana Life Sciences had 1 more articles in the media than Prothena. MarketBeat recorded 8 mentions for Tiziana Life Sciences and 7 mentions for Prothena. Tiziana Life Sciences' average media sentiment score of 1.93 beat Prothena's score of 0.35 indicating that Tiziana Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prothena	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Tiziana Life Sciences	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Prothena presently has a consensus price target of $23.75, suggesting a potential upside of 169.58%. Given Prothena's stronger consensus rating and higher probable upside, equities analysts plainly believe Prothena is more favorable than Tiziana Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prothena	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Tiziana Life Sciences	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Tiziana Life Sciences beats Prothena on 8 of the 14 factors compared between the two stocks.

How does Tiziana Life Sciences compare to Benitec Biopharma?

Tiziana Life Sciences (NASDAQ:TLSA) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and dividends.

Benitec Biopharma has a consensus price target of $24.80, suggesting a potential upside of 84.04%. Given Benitec Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Benitec Biopharma is more favorable than Tiziana Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tiziana Life Sciences	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Benitec Biopharma	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

Tiziana Life Sciences' return on equity of 0.00% beat Benitec Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tiziana Life Sciences	N/A	N/A	N/A
Benitec Biopharma	N/A	-34.82%	-34.11%

In the previous week, Tiziana Life Sciences had 8 more articles in the media than Benitec Biopharma. MarketBeat recorded 8 mentions for Tiziana Life Sciences and 0 mentions for Benitec Biopharma. Tiziana Life Sciences' average media sentiment score of 1.93 beat Benitec Biopharma's score of 0.00 indicating that Tiziana Life Sciences is being referred to more favorably in the media.

Company	Overall Sentiment
Tiziana Life Sciences	Very Positive
Benitec Biopharma	Neutral

Tiziana Life Sciences has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market. Comparatively, Benitec Biopharma has a beta of 0.28, indicating that its share price is 72% less volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tiziana Life Sciences	N/A	N/A	-$18.43M	N/A	N/A
Benitec Biopharma	N/A	N/A	-$37.92M	-$1.14	N/A

52.2% of Benitec Biopharma shares are held by institutional investors. 39.8% of Tiziana Life Sciences shares are held by company insiders. Comparatively, 4.8% of Benitec Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Tiziana Life Sciences beats Benitec Biopharma on 7 of the 11 factors compared between the two stocks.

How does Tiziana Life Sciences compare to Crescent Biopharma?

Tiziana Life Sciences (NASDAQ:TLSA) and Crescent Biopharma (NASDAQ:CBIO) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, media sentiment, valuation, risk and analyst recommendations.

75.2% of Crescent Biopharma shares are owned by institutional investors. 39.8% of Tiziana Life Sciences shares are owned by company insiders. Comparatively, 24.8% of Crescent Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Tiziana Life Sciences' return on equity of 0.00% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tiziana Life Sciences	N/A	N/A	N/A
Crescent Biopharma	N/A	-101.50%	-86.86%

In the previous week, Crescent Biopharma had 2 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 10 mentions for Crescent Biopharma and 8 mentions for Tiziana Life Sciences. Tiziana Life Sciences' average media sentiment score of 1.93 beat Crescent Biopharma's score of 0.13 indicating that Tiziana Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tiziana Life Sciences	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Crescent Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tiziana Life Sciences has a beta of 0.49, suggesting that its stock price is 51% less volatile than the broader market. Comparatively, Crescent Biopharma has a beta of 1.23, suggesting that its stock price is 23% more volatile than the broader market.

Crescent Biopharma has a consensus target price of $29.40, indicating a potential upside of 74.35%. Given Crescent Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Crescent Biopharma is more favorable than Tiziana Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tiziana Life Sciences	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Crescent Biopharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Tiziana Life Sciences has higher earnings, but lower revenue than Crescent Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tiziana Life Sciences	N/A	N/A	-$18.43M	N/A	N/A
Crescent Biopharma	$10.84M	57.78	-$153.94M	-$6.72	N/A

Summary

Crescent Biopharma beats Tiziana Life Sciences on 8 of the 13 factors compared between the two stocks.

How does Tiziana Life Sciences compare to Cabaletta Bio?

Cabaletta Bio (NASDAQ:CABA) and Tiziana Life Sciences (NASDAQ:TLSA) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership, media sentiment and dividends.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.96	N/A
Tiziana Life Sciences	N/A	N/A	-$18.43M	N/A	N/A

Cabaletta Bio currently has a consensus target price of $15.50, indicating a potential upside of 460.58%. Given Cabaletta Bio's stronger consensus rating and higher probable upside, analysts plainly believe Cabaletta Bio is more favorable than Tiziana Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Tiziana Life Sciences	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Cabaletta Bio has a beta of 3.3, suggesting that its stock price is 230% more volatile than the broader market. Comparatively, Tiziana Life Sciences has a beta of 0.49, suggesting that its stock price is 51% less volatile than the broader market.

In the previous week, Tiziana Life Sciences had 7 more articles in the media than Cabaletta Bio. MarketBeat recorded 8 mentions for Tiziana Life Sciences and 1 mentions for Cabaletta Bio. Tiziana Life Sciences' average media sentiment score of 1.93 beat Cabaletta Bio's score of 1.67 indicating that Tiziana Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cabaletta Bio	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Tiziana Life Sciences	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Tiziana Life Sciences' return on equity of 0.00% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cabaletta Bio	N/A	-131.58%	-96.46%
Tiziana Life Sciences	N/A	N/A	N/A

Summary

Tiziana Life Sciences beats Cabaletta Bio on 5 of the 9 factors compared between the two stocks.

Get Tiziana Life Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TLSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TLSA vs. The Competition

Export

Metric	Tiziana Life Sciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$125.22M	$3.71B	$7.04B	$12.92B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	N/A	9.08	269.95	24.78
Price / Sales	N/A	1,267.38	650.49	107.95
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	N/A	17.64	11.25	6.43
Net Income	-$18.43M	-$13.25M	$3.45B	$347.27M
7 Day Performance	1.52%	5.21%	3.49%	2.53%
1 Month Performance	-20.00%	-1.94%	-0.66%	-1.03%
1 Year Performance	-55.27%	60.76%	77.20%	23.28%

Tiziana Life Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TLSA Tiziana Life Sciences	1.8329 of 5 stars	$0.99 -0.6%	N/A	-54.5%	$126.24M	N/A	N/A	8	Positive News Gap Up High Trading Volume
KYTX Kyverna Therapeutics	2.1211 of 5 stars	$7.89 +1.8%	$30.00 +280.2%	+145.7%	$480.24M	N/A	N/A	96	News Coverage Upcoming Earnings
PRTA Prothena	2.8749 of 5 stars	$8.74 +1.8%	$23.75 +171.9%	+13.9%	$457.51M	$57.94M	N/A	130	Earnings Report
BNTC Benitec Biopharma	1.3727 of 5 stars	$13.30 +1.3%	$24.80 +86.5%	+15.5%	$457.20M	N/A	N/A	20
CBIO Crescent Biopharma	2.4036 of 5 stars	$16.58 +0.9%	$29.40 +77.3%	+31.1%	$456.95M	$10.84M	N/A	50

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TLSA) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tiziana Life Sciences (TLSA) Competitors

TLSA vs. KYTX, PRTA, BNTC, CBIO, and CABA

How does Tiziana Life Sciences compare to Kyverna Therapeutics?

Summary

How does Tiziana Life Sciences compare to Prothena?

Summary

How does Tiziana Life Sciences compare to Benitec Biopharma?

Summary

How does Tiziana Life Sciences compare to Crescent Biopharma?

Summary

How does Tiziana Life Sciences compare to Cabaletta Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLSA vs. The Competition

Tiziana Life Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tiziana Life Sciences (TLSA) Competitors

TLSA vs. KYTX, PRTA, BNTC, CBIO, and CABA

How does Tiziana Life Sciences compare to Kyverna Therapeutics?

Do institutionals & insiders believe in KYTX or TLSA?

Which has better earnings & valuation, KYTX or TLSA?

Which has more risk & volatility, KYTX or TLSA?

Is KYTX or TLSA more profitable?

Does the media refer more to KYTX or TLSA?

Do analysts prefer KYTX or TLSA?

Summary

How does Tiziana Life Sciences compare to Prothena?

Which has more volatility & risk, PRTA or TLSA?

Which has better earnings & valuation, PRTA or TLSA?

Do institutionals and insiders hold more shares of PRTA or TLSA?

Is PRTA or TLSA more profitable?

Does the media prefer PRTA or TLSA?

Do analysts prefer PRTA or TLSA?

Summary

How does Tiziana Life Sciences compare to Benitec Biopharma?

Do analysts prefer TLSA or BNTC?

Is TLSA or BNTC more profitable?

Does the media refer more to TLSA or BNTC?

Which has more volatility and risk, TLSA or BNTC?

Which has stronger valuation & earnings, TLSA or BNTC?

Do institutionals & insiders hold more shares of TLSA or BNTC?

Summary

How does Tiziana Life Sciences compare to Crescent Biopharma?

Do institutionals and insiders believe in TLSA or CBIO?

Is TLSA or CBIO more profitable?

Does the media refer more to TLSA or CBIO?

Which has more volatility & risk, TLSA or CBIO?

Do analysts prefer TLSA or CBIO?

Which has higher earnings & valuation, TLSA or CBIO?

Summary

How does Tiziana Life Sciences compare to Cabaletta Bio?

Which has better valuation & earnings, CABA or TLSA?

Do analysts recommend CABA or TLSA?

Which has more risk & volatility, CABA or TLSA?

Does the media refer more to CABA or TLSA?

Is CABA or TLSA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLSA vs. The Competition

Tiziana Life Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools